Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease

Type 2 diabetes mellitus (T2DM) is associated with cardiovascular disease (CVD) and sodium glucose cotransporter 2 inhibitors, as oral medications for T2DM treatment have shown the potential to improve vascular dysfunction. The aim of this study was to evaluate the ability of canagliflozin (Cana) to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xueliang, Wang, Zhe, Liu, Di, Jiang, Hao, Cai, Chao, Li, Guoyun, Yu, Guangli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905428/
https://www.ncbi.nlm.nih.gov/pubmed/35281938
http://dx.doi.org/10.3389/fphar.2022.839640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905428/
https://www.ncbi.nlm.nih.gov/pubmed/35281938
http://dx.doi.org/10.3389/fphar.2022.839640

Ejemplares similares